MAPK signaling in cisplatin-induced death: Predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells

Carcinogenesis

Volumn 34, Issue 1, 2013, Pages 38-47

  Guégan, Jean Philippe ^a   Ezan, Frédéric ^a   Théret, Nathalie ^a   Langoüt, Sophie ^a   Baffet, Georges ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN NOXA;

ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT;

EID: 84872141798     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs317     Document Type: Article

References (50)

1. El-Serag, H.B. (2011) Hepatocellular carcinoma. N. Engl. J. Med., 365, 1118-1127.
2. Ishikawa, T. (2009) Future perspectives on the treatment of hepatocellular carcinoma with cisplatin. World J. Hepatol., 1, 8-16.
3. Galluzzi, L. et al. (2012) Molecular mechanisms of cisplatin resistance. Oncogene, 31, 1869-1883.
4. Shapiro, G.I. et al. (1999) Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest., 104, 1645-1653.
5. Gonzalez, V.M. et al. (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol., 59, 657-663.
6. Wang, D. et al. (2005) Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov., 4, 307-320.
7. Brozovic, A. et al. (2007) Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett., 251, 1-16.
8. Wang, X. et al. (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem., 275, 39435-39443.
9. Zhuang, S. et al. (2006) A death-promoting role for extracellular signalregulated kinase. J. Pharmacol. Exp. Ther., 319, 991-997.
10. Sheridan, C. et al. (2010) An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. Oncogene, 29(49):6428-6441.
11. Choi, B.K. et al. (2004) Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells. Neurotoxicology, 25, 915-924.
12. Woessmann, W. et al. (2002) Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother. Pharmacol., 50, 397-404.
13. Lu, Y. et al. (2007) The mode of cisplatin-induced cell death in CYP2E1-overexpressing HepG2 cells: modulation by ERK, ROS, glutathione, and thioredoxin. Free Radic. Biol. Med., 43, 1061-1075.
14. Jo, S.K. et al. (2005) MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int., 67, 458-466.
15. Persons, D.L. et al. (1999) Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res., 5, 1007-1014.
16. Wang, J. et al. (2011) Bim protein degradation contributes to cisplatin resistance. J. Biol. Chem., 286, 22384-22392.
17. Raman, M. et al. (2007) Differential regulation and properties of MAPKs. Oncogene, 26, 3100-3112.
18. Shaul, Y. et al. (2007) The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim. Biophys. Acta Mol. Cell Res., 1773, 1213-1226.
19. Giroux, S. et al. (1999) Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol., 9, 369-372.
20. Saba-El-Leil, M.K. et al. (2003) An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Rep., 4, 964-968.
21. Pages, G. et al. (1999) Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science, 286, 1374-1377.
22. Belanger, L.F. et al. (2003) Mek2 is dispensable for mouse growth and development. Mol. Cell. Biol., 23, 4778-4787.
23. Bessard, A. et al. (2008) RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene, 27, 5315-5325.
24. Shama, J. et al. (2008) Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells. Biochem. Biophys. Res. Commun., 372, 845-849.
25. Scholl, F.A. et al. (2009) Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia. Cancer Res., 69, 3772-3778.
26. Lloyd, A.C. (2006) Distinct functions for ERKs? J. Biol., 5, 13.
27. Lefloch, R. et al. (2007) Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol. Cell. Biol., 28, 511-527.
28. Voisin, L. et al. (2010) Genetic demonstration of a redundant role of extracellular signal-regulated kinase 1 (ERK1) and ERK2 mitogen-activated protein kinases in promoting fibroblast proliferation. Mol. Cell. Biol., 30, 2918-2932.
29. Lefloch, R. et al. (2009) Total ERK1/2 activity regulates cell proliferation. Cell Cycle, 8, 705-711.
30. Liu, J. et al. (1998) Metallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity. Toxicol. Appl. Pharmacol., 149, 24-31.
31. Rageul, J. et al. (2011) The knock-down of ERCC1 but not of XPF causes multinucleation. DNA Repair (Amst.), 10, 978-990.
32. Fremin, C. et al. (2012) The complexity of ERK1 and ERK2 MAPKs in multiple hepatocyte fate responses. J. Cell Physiol. 227(1):59-69.
33. Tournier, C. et al. (2000) Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science, 288, 870-874.
34. Sanchez-Perez, I. et al. (1999) Lack of c-Jun activity increases survival to cisplatin. FEBS Lett., 453, 151-158.
35. Wang, Z. et al. (2006) Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res., 66, 8870-8877.
36. Lu, R. et al. (2007) Inhibition of the extracellular signal-regulated kinase/ mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells. J. Biol. Chem., 282, 12249-12259.
37. Skarpen, E. et al. (2008) MEK1 and MEK2 regulate distinct functions by sorting ERK2 to different intracellular compartments. FASEB J., 22, 466-476.
38. Gailhouste, L. et al. (2010) RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo. Int. J. Cancer, 126, 1367-1377.
39. Datta, K. et al. (2004) Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides. Cancer Gene Ther., 11, 525-531.
40. Villunger, A. et al. (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science, 302, 1036-1038.
41. Frémin, C. et al. (2009) Multiple division cycles and long-term survival of hepatocytes are distinctly regulated by extracellular signal-regulated kinases ERK1 and ERK2. Hepatology, 49, 930-939.
42. Bourcier, C. et al. (2006) p44 mitogen-activated protein kinase (extracellular signal-regulated kinase 1)-dependent signaling contributes to epithelial skin carcinogenesis. Cancer Res., 66, 2700-2707.
43. Guihard, S. et al. (2010) The MAPK ERK1 is a negative regulator of the adult steady-state splenic erythropoiesis. Blood, 115, 3686-3694.
44. Hara, H. et al. (2009) Zinc induces expression of the BH3-only protein PUMA through p53 and ERK pathways in SH-SY5Y neuroblastoma cells. Neurochem. Res., 34, 1498-1506.
45. Liu, J. et al. (2008) ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol., 295, H1956-H1965.
46. Balmanno, K. et al. (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ., 16, 368-377.
47. Bourbonnais, E. et al. (2012) Liver fibrosis protects mice from acute hepatocellular injury. Gastroenterology, 142(1): 130-139.
48. Arany, I. et al. (2004) Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am. J. Physiol. Renal Physiol., 287, F543-F549.
49. di Mari, J.F. et al. (1999) MAPK activation determines renal epithelial cell survival during oxidative injury. Am. J. Physiol., 277, F195-F203.
50. Fang, X. et al. (1999) Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene, 18, 6635-6640.